Arboviral infections, especially Dengue, Chikungunya and Zika have been composed of a severe and growing global threat in the populations' health. 1 The co-circulation of the four Dengue virus serotypes and the two most recently introduced virus in Brazil, Chikungunya and Zika (2015-2016), and in other countries in the Americas, these viruses have caused a dramatic increase such as, the number of the cases, complications and deaths in the region. Recently, the introduction of the Zika virus in Brazil has brought an unprecedented number of microcephaly cases attributed to the congenital virus infection, particularly in the Northeast region. 2 In the world, it is estimated that 90% of the pregnancies which occur annually in endemic areas of arboviruses, about 10% are exposed to the infection. 3 Most of the Arboviral infections are asymptomatic or manifest as acute infectious of lesser severity, whose initial symptoms are usually, fever, headache, myalgia, arthralgia and maculopapular rash, these are non-specific and similar among each other. 4, 5 In pregnant women, although the manifestations are usually indistinguishable from the rest of the population, the risk of progression in the severe forms of the disease are shock and hemorrhagic syndromes, which are the highest, according to studies. 3 Similarly, Arboviral infection in pregnant women increases the risk of pregnancy complications, such as, preterm labor, preterm placental abruption, preeclampsia, vaginal bleeding and maternal death, which may also affect the concept's health by transmitting of the virus via the placenta or during childbirth. However, despite the potential risk of arboviruses in pregnant woman and her fetus' health, this draws attention to the scarcity or near-absence of the detailed clinical data enabling early detection of complications that may arise during the pregnancy. In addition, preventive and therapeutic measures aimed for these diseases are not available yet.
